Soblidotin in Treating Patients With Progressive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT00061854
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
INDUSTRY
Sponsor class
Conditions
Lung Cancer
Interventions
DRUG:
soblidotin
Sponsor
Daiichi Sankyo